In May 2007, the company pleaded guilty to misleading the public about OxyContin's risk of addiction and agreed to pay (equivalent to approximately $M in ) in one of the largest pharmaceutical settlements in U.S. history. The company's president (Michael Friedman), top lawyer (Howard R. Udell), and former chief medical officer (Paul D. Goldenheim) pleaded guilty as individuals to misbranding charges, a criminal violation and agreed to pay a total of in fines. Friedman, Udell, and Goldenheim agreed to pay , and , respectively. In addition, three top executives were charged with a felony and sentenced to 400 hours of community service in drug treatment programs.